NCT06053021

Antiplatelet Therapy for AIS Patients With Thrombocytopenia

Antiplatelet Therapy for Acute Ischemic Stroke Patients With Thrombocytopenia

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 1,200 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.

Detailed description

Antiplatelet therapy is widely used in non-cardiogenic AIS patients for secondary prevention. However, it may also increase the risk of bleeding complications, especially in patients with thrombocytopenia. The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.

Conditions

• Acute Ischemic Stroke
• Thrombocytopenia

Interventions

Type	Name	Description
DRUG	aspirin, clopidogrel, cilostazol, and dipyridamole	Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.

Timeline

• Start date: 2023-09-15
• Primary completion: 2025-10-01
• Completion: 2026-01-01
• First posted: 2023-09-25
• Last updated: 2023-10-18

Locations

1 site across 1 country: China